List of Triumeq drug patents
Triumeq is owned by Viiv Hlthcare.
Triumeq contains Abacavir Sulfate; Dolutegravir Sodium; Lamivudine.
Triumeq has a total of 2 drug patents out of which 0 drug patents have expired.
Triumeq was authorised for market use on 22 August, 2014.
Triumeq is available in tablet;oral dosage forms.
The generics of Triumeq are possible to be released after 08 December, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 22 August, 2014
Treatment: NA
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic